Skip to main content

Advertisement

Table 2 Distribution of genotypes and the relationship between polymorphisms of studied genes and the risk of female breast cancer in Inuit

From: Polymorphisms in Phase I and Phase II genes and breast cancer risk and relations to persistent organic pollutant exposure: a case–control study in Inuit women

Gene Genotype Case N (%) Control N (%) P (χ2) Odds ratio (95% CI); p-value
Crude Age adjusted Age and cotinine adjusted
CYP1A1 (Ile462Val) Ile/Ile 4 (13.3) 32 (28.3) .241* 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Ile/Val 17 (56.7) 54 (47.8)   2.52 (0.78-8.15); p = 0.123 2.52 (0.78-8.14); p = 0.124 5.08 (1.19-21.6); p = 0.028
Val/val 9 (30.0) 27 (23.9)   2.67 (0.74-9.63); P = 0.134 2.66 (0.73-9.67); p = 0.138 3.31 (0.69-15.9); p = 0.135
Ile/val + Val/val 26 (86.7) 81 (71.7) .104** 2.57 (0.83-7.95); P = 0.102 2.56 (0.83-7.95); p = 0.103 4.35 (1.08-17.5); p = 0.038
Val allele 35 (58.3) 108 (47.8)     
CYP1B1 (Leu432Val) Leu/Leu 26 (83.9) 79 (71.2) .159 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Leu/val 4 (12.9) 31 (27.9)   0.39 (0.13-1.21); p = 0.105 0.39 (0.13-1.22); p = 0.105 0.39 (0.094-1.45); p = 0.174
Val/val 1 (3.2) 1 (0.9)   3.04 (0.18-50.3); p = 0.438 3.03 (0.18-50.1); p = 0.439 -
Leu/val + Val/val 5 (16.1) 32 (28.8) .174 0.48 (0.17-1.35); p = 0.161 0.47 (0.17-1.34); p = 0.160 0.39 (0.094-1.45); p = 0.174
Val allele 6 (9.7) 33 (14.9)     
COMT (Val158Met) Val/val 7 (22.6) 19 (16.8) .504 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Val/Met 11 (35.5) 53 (46.9)   0.56 (0.19-1.66); p = 0.299 0.56 (0.19-1.67); p = 0.300 0.65 (0.19-2.16); p = 0.476
Met/met 13 (41.9) 41 (36.3)   0.86 (0.29-2.53); p = 0.783 0.87 (0.29-2.56); P = 0.871 0.65 (0.19-2.26); p = 0.498
Val/Met-Met/Met 24 (77.4) 94 (83.2) .441 0.69 (0.26-1.84); p = 0.461 0.69 (0.26-1.85); P = 0.463 0.65 (0.22-1.93); p = 0.435
Met allele 37 (59.7) 135 (59.7)     
CYP17 (−34 T > C) TT (A1/A1) 12 (40) 24 (21.2) .107 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
TC (A1/A2) 12 (40) 57 (50.4)   0.41 (0.16-1.05); p = 0.062 0.40 (0.16-1.03); p = 0.057 0.35 (0.12-1.05); p = 0.06
CC (A2/A2) 6 (20) 32 (28.3)   0.36 (0.12-1.10); p = 0.073 0.35 (0.11-1.03); p = 0.067 0.25 (0.063-0.95); P = 0.042
A1/A2 + A2/A2 18 (60) 89 (78.8) .054 0.39 (0.16-0.93); p = 0.033 0.38 (0.16-1.04); p = 0.030 0.34 (0.12-0.94); P = 0.038
A2 allele 24 (40) 121 (53.5)     
CYP19 (C > T) CC 23 (74.2) 79 (69.3) .424 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
CT 8 (25.8) 29 (25.4)   0.95 (0.38-2.36); p = 0.908 0.94 (0.38-2.35) p = 0.944 1.29 (0.45-3.71); p = 0.639
TT 0 (0) 6 (5.3)   - - -
CT + TT 8 (25.8) 35 (30.7) .662 0.79 (0.32-1.95); p = 0.608 0.78 (0.32-1.93); P = 0.594 1.13 (0.39-3.23); p = 0.821
T allele 8 (12.9) 41 (18)     
CYP19 (TTTA)n F (7–10) 27 (87.1) 76 (75.2) .317 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
SF 4 (12.9) 22 (21.8)   0.51 (0.16-1.62); p = 0.255 0.50 (0.16-1.58); p = 0.236 0.70 (0.2-2.45); p = 0.577
S (11–13) 0 (0) 3 (3.0)   - - -
SF + S 4 (12.9) 25 (24.8) .217 0.45 (0.14-1.41); p = 0.17 0.44 (0.14-1.39); p = 0.160 0.70 (0.20-2.45); p = 0.577
S allele 4 (6.5) 28 (13.9)     
BRCA1 (Cys39Gly) Cys/Cys 28 (90.3) 106 (97.2) .122 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Cys/Gly 3 (9.7) 3 (2.8)   3.79 (0.73-19.7); p = 0.115 4.29 (0.77-23.9); p = 0.097 5.14(0.45-58.9); p = 0.189
Gly /Gly 0 (0) 0 (0)     
Gly allele 3 (4.8) 3 (1.4)     
  1. *p-value for comparison between the 3 genotypes (wt/wt; wt/var; var/var) using chi-2 analysis.
  2. **p-value for comparison between the wt/wt and wt/var+var/var (dominant model).
  3. Boldface indicate significance at p<0.05.